Kn. Thimmaiah et al., CHARACTERIZATION OF 2-CHLORO-N-10-SUBSTITUTED PHENOXAZINES FOR REVERSING MULTIDRUG-RESISTANCE IN CANCER-CELLS, Oncology research, 10(1), 1998, pp. 29-41
Twenty-one 2-chloro-N-10-substituted phenoxazines have been synthesize
d and characterized as potential modulators of multidrug resistance (M
DR). Many of the compounds, at a concentration of 100 mu M, enhanced a
ccumulation of vinblastine (VLB) in drug-resistant KB8-5 cells to a gr
eater extent than the same concentration of verapamil (VRP). However,
the effects on VLB accumulation were specific, because these derivativ
es had little activity in the parental drug-sensitive line KB3-1. The
compounds slowed the efflux of VLB from KB8-5 cells, suggesting that t
he chlorophenoxazines, like VRP, can inhibit P-glycoprotein (P-gp)-med
iated efflux of VLB from this cell line. Two of the chlorophenoxazine
derivatives, and also VRP, were able to stimulate the vanadate-sensiti
ve ATPase activity attributable to P-gp in membranes isolated from MDR
1 baculovirus-infected Sf9 cells. This result suggests that these modu
lators exert their effect by directly interacting with P-gp. Apart fro
m the parent unsubstituted molecule, 2-chlorophenoxazine, there was a
good correlation between log(10)P and the ability of the compounds to
enhance VLB accumulation in KB8-5. This suggests that lipophilicity of
a modulator is important, but is not the sole determinant of potency.
Within this series of compounds, the optimal structural features for
MDR modulation include a hydrophobic phenoxazine ring with a -Cl atom
in the C-2 position and a tertiary amine group four carbons from the t
ricyclic ring. Many of the agents at the IC10 concentration completely
reversed the 37-fold VLB resistance in KB8-5 cells. The most active a
gents in KB8-5 were able to partially reverse VLB resistance in an MDR
colon carcinoma cell line GC(3)/c1 and completely reversed the 86-fol
d VLB resistance in the MDR1-overexpressing breast carcinoma cell line
BC19/3. These same agents could only partially sensitize BC19/3 cells
to taxol and doxorubicin, suggesting that the chlorophenoxazine deriv
atives show some specificity for modulating VLB resistance.